Pancreatic Cancer Pipeline Insight 2025: Breaking Barriers with Novel Targets and Multi-Modal Therapies | DelveInsight

Pancreatic cancer remains one of the deadliest malignancies globally, with a 5-year survival rate lingering in the single digits due to late diagnosis, rapid disease progression, and limited therapeutic options. Traditional chemotherapies like FOLFIRINOX and gemcitabine-based regimens offer modest benefits, and current immunotherapies have shown limited efficacy in this immunocold tumor type. However, the therapeutic landscape is beginning to shift. DelveInsight's "Pancreatic Cancer - Pipeline Insight, 2025" profiles over 200 investigational therapies aimed at redefining the standard of care through novel mechanisms and combination approaches.

Leading candidates in the pipeline target key oncogenic drivers such as KRAS G12D/V mutations, TP53, and CDKN2A. Precision oncology strategies are advancing with KRAS inhibitors (e.g., Mirati Therapeutics, Revolution Medicines), DNA damage response modulators like PARP and ATR inhibitors, and tumor microenvironment disruptors such as CD40 agonists and CXCR4 antagonists. Immune checkpoint combinations, oncolytic viruses, T-cell engagers, and neoantigen vaccines are being explored to transform pancreatic cancer into an immuno-responsive disease.

Biopharma companies, including ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others are leading development efforts, with several mid-to-late stage candidates showing promise in improving progression-free survival and overall response rates. DelveInsight's report also covers emerging biomarkers, adaptive trial designs, and innovative delivery platforms such as nanoparticle-based therapeutics and intratumoral injectables. As the industry pivots towards personalized, multi-modal approaches, the next wave of therapies offers cautious optimism for improved outcomes in this high-unmet-need oncology segment.

Interested in learning more about the current treatment landscape and the key drivers shaping the pancreatic cancer pipeline? Click here: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Pancreatic Cancer Pipeline Report
• DelveInsight's Pancreatic Cancer pipeline analysis depicts a strong space with 170+ active players working to develop 200+ pipeline drugs for Pancreatic Cancer treatment.
• The leading Pancreatic Cancer companies include ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others are evaluating their lead assets to improve the Pancreatic Cancer treatment landscape.
• Key Pancreatic Cancer pipeline therapies in various stages of development include Eryaspase, Fuzuloparib, Pamrevlumab, NIS793, Masitinib, Glufosfamide, Devimistat, SBP-101, TAS-102, RAIN-32, RXC004, LY3214996, Lurbinectedin, IMM-101, GSK2256098, Belzutifan, Atezolizumab, Anamorelin, DK210, CX-5461, CUE-102, CT-0508, CCX872-B, BI 765049, BCA101, AB680, MB1707, IM96 CAR-T cells, SD-101, ONO 7913, PY159, XL888, WM-S1-030, ABTL0812, A2B530, A166, NLM-001, Ivaltinostat, ELI-002, TPX4589, IMM-1-104, PTX_C1, ACB2003.4, Research program, OPN-FMRP, PanCaVax - Pancreatic Cancer Vaccine, Research Program 2, and others.
• In July 2025, Arcus Biosciences announced that the FDA granted Orphan Drug Designation to quemliclustat, its investigational CD73 inhibitor, for the treatment of pancreatic cancer.
• In June 2025, Revolution Medicines received FDA Breakthrough Therapy Designation for daraxonrasib, its RAS(ON) multi-selective inhibitor, for treating previously treated metastatic pancreatic cancer (PDAC) in patients with KRAS G12 mutations.
• In June 2025, ImmunityBio, Inc. (NASDAQ: IBRX) presented data at ASCO 2025 showing that ANKTIVA® combined with CAR-NK therapy is the first known treatment to reverse lymphopenia, a major contributor to early cancer mortality. The results highlight a significant overall survival benefit in patients with advanced pancreatic cancer, supporting the therapy's potential across multiple tumor types.
• In March 2025, Boan Biotechnology (06955.HK) announced that its targeted CD228 antibody-drug conjugate, BA1302, received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for squamous non-small cell lung cancer and pancreatic cancer.
• In February 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) status to nogapendekin alfa (Anktiva) and CAR-NK (PD-L1 t-haNK) for their potential to reverse lymphopenia in patients undergoing chemotherapy/radiotherapy and to treat metastatic pancreatic cancer.
• In February 2025, Alligator Bioscience announced the successful completion of its End of Phase 2 (EOP2) interaction with the FDA, paving the way for a Phase 3 trial in 2025. The trial will test mitazalimab as a first-line treatment for metastatic pancreatic cancer in combination with mFOLFIRINOX.

Request a sample and discover the recent breakthroughs happening in the pancreatic cancer pipeline landscape at https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pancreatic Cancer Overview
Pancreatic cancer is a highly aggressive malignancy that originates in the tissues of the pancreas, an organ located behind the lower part of the stomach. It is often referred to as a "silent disease" because symptoms typically do not appear until the cancer is advanced. The most common type is pancreatic ductal adenocarcinoma (PDAC), which arises from the cells lining the pancreatic ducts.

Due to late diagnosis, rapid disease progression, and limited treatment options, pancreatic cancer has a poor prognosis and is one of the leading causes of cancer-related deaths globally. Risk factors include smoking, chronic pancreatitis, diabetes, family history, obesity, and certain genetic mutations (e.g., BRCA1/2). Treatment strategies include surgery, chemotherapy, radiation, and targeted therapies, but only a small percentage of patients are eligible for curative surgery. Ongoing research focuses on improving early detection and developing novel therapies to enhance survival outcomes.

Find out more about pancreatic cancer medication at https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pancreatic Cancer Treatment Analysis: Drug Profile
Pamrevlumab: FibroGen
Pamrevlumab is a first-in-class monoclonal antibody developed by FibroGen that targets connective tissue growth factor (CTGF), implicated in fibrosis and tumor progression. It has received Orphan Drug and Fast Track designations from the FDA for pancreatic cancer and is currently in Phase III clinical trials.

Masitinib: AB Science
Masitinib (AB-1010) is an orally administered tyrosine kinase inhibitor developed by AB Science, targeting c-KIT and other kinases like Fyn, Lyn, and PDGFR. It is being studied in Phase III trials for the treatment of metastatic pancreatic cancer.

Glufosfamide: Eleison Pharmaceuticals
Glufosfamide is a glucose-linked alkylating agent designed for targeted chemotherapy. The glucose moiety allows preferential uptake by tumor cells, where it releases the active drug. It is currently in Phase III trials for pancreatic cancer.

Quemliclustat: Arcus Biosciences
Quemliclustat is a CD73 inhibitor that reduces adenosine production, thereby enhancing immune response. Developed by Arcus Biosciences, it is being evaluated in Phase III trials for pancreatic cancer, administered both orally and intravenously.

Learn more about the novel and emerging pancreatic cancer pipeline therapies at https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pancreatic Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Pancreatic Cancer Pipeline Report
• Coverage: Global
• Key Pancreatic Cancer Companies: ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
• Key Pancreatic Cancer Pipeline Therapies: Eryaspase, Fuzuloparib, Pamrevlumab, NIS793, Masitinib, Glufosfamide, Devimistat, SBP-101, TAS-102, RAIN-32, RXC004, LY3214996, Lurbinectedin, IMM-101, GSK2256098, Belzutifan, Atezolizumab, Anamorelin, DK210, CX-5461, CUE-102, CT-0508, CCX872-B, BI 765049, BCA101, AB680, MB1707, IM96 CAR-T cells, SD-101, ONO 7913, PY159, XL888, WM-S1-030, ABTL0812, A2B530, A166, NLM-001, Ivaltinostat, ELI-002, TPX4589, IMM-1-104, PTX_C1, ACB2003.4, Research program, OPN-FMRP, PanCaVax - Pancreatic Cancer Vaccine, Research Program 2, and others.

To dive deep into rich insights for drugs used for pancreatic cancer treatment, visit: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Pancreatic Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Pancreatic Cancer Pipeline Therapeutics
6. Pancreatic Cancer Pipeline: Late-Stage Products (Phase III)
7. Pancreatic Cancer Pipeline: Mid-Stage Products (Phase II)
8. Pancreatic Cancer Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.